Common Interactions between S100A4 and S100A9 Defined by a Novel Chemical Probe

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Björk, Per ^b   Källberg, Eva ^a   Wellmar, Ulf ^b   Riva, Matteo ^a   Olsson, Anders ^b   He, Zhifei ^a   Törngren, Marie ^b   Liberg, David ^b   Ivars, Fredrik ^a   Leanderson, Tomas ^a  

^a LUND UNIVERSITY   (Sweden)

^b Active Biotech Research AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CALCIUM ION; CALGRANULIN B; CALVASCULIN; CD11B ANTIGEN; OXYCLOZANIDE; TOLL LIKE RECEPTOR 4; ZINC ION;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIMERIZATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; EXTRACELLULAR SPACE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; SPLEEN CELL; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD11B; BLOTTING, WESTERN; CALGRANULIN B; CELL LINE, TUMOR; CELL PROLIFERATION; DIMERIZATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EXTRACELLULAR FLUID; GENE EXPRESSION REGULATION; HUMANS; LYMPHOMA; MICE; MICE, INBRED C57BL; MOLECULAR PROBES; MOLECULAR STRUCTURE; OXYCLOZANIDE; S100 PROTEINS; TOLL-LIKE RECEPTOR 4; ZINC;

EID: 84877298739     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063012     Document Type: Article

References (32)

1. Marenholz I, Heizmann CW, Fritz G, (2004) S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322: 1111-1122.
2. Heizmann CW, Fritz G, Schafer BW, (2002) S100 proteins: structure, functions and pathology. Front Biosci 7: d1356-1368.
3. Davies BR, Davies MP, Gibbs FE, Barraclough R, Rudland PS, (1993) Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene 8: 999-1008.
4. Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Florenes VA, et al. (1996) Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 56: 5490-5498.
5. Garrett SC, Varney KM, Weber DJ, Bresnick AR, (2006) S100A4, a mediator of metastasis. J Biol Chem 281: 677-680.
6. Xie R, Schlumbrecht MP, Shipley GL, Xie S, Bassett RL Jr, et al. (2009) S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling. Lab Invest 89: 937-947.
7. Rudland PS, Platt-Higgins A, Renshaw C, West CR, Winstanley JH, et al. (2000) Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 60: 1595-1603.
8. Maelandsmo GM, Florenes VA, Nguyen MT, Flatmark K, Davidson B, (2009) Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites. Tumour Biol 30: 15-25.
9. Boye K, Nesland JM, Sandstad B, Maelandsmo GM, Flatmark K, (2010) Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer 46: 2919-2925.
10. Yammani RR, Carlson CS, Bresnick AR, Loeser RF, (2006) Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products. Arthritis Rheum 54: 2901-2911.
11. Miranda KJ, Loeser RF, Yammani RR Sumoylation and nuclear translocation of S100A4 regulate IL-1beta-mediated production of matrix metalloproteinase-13. J Biol Chem 285: 31517-31524.
12. Kriajevska M, Bronstein IB, Scott DJ, Tarabykina S, Fischer-Larsen M, et al. (2000) Metastasis-associated protein Mts1 (S100A4) inhibits CK2-mediated phosphorylation and self-assembly of the heavy chain of nonmuscle myosin. Biochim Biophys Acta 1498: 252-263.
13. Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Kriajevska M, et al. (2001) The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene 20: 4685-4695.
14. Foell D, Wittkowski H, Vogl T, Roth J, (2007) S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 81: 28-37.
15. Roth J, Vogl T, Sorg C, Sunderkotter C, (2003) Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends Immunol 24: 155-158.
16. Foell D, Roth J, (2004) Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 50: 3762-3771.
17. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, et al. (2005) Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 11: 5146-5152.
18. Itou H, Yao M, Fujita I, Watanabe N, Suzuki M, et al. (2002) The crystal structure of human MRP14 (S100A9), a Ca(2+)-dependent regulator protein in inflammatory process. J Mol Biol 316: 265-276.
19. Lominadze G, Rane MJ, Merchant M, Cai J, Ward RA, et al. (2005) Myeloid-related protein-14 is a p38 MAPK substrate in human neutrophils. J Immunol 174: 7257-7267.
20. Manitz MP, Horst B, Seeliger S, Strey A, Skryabin BV, et al. (2003) Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro. Mol Cell Biol 23: 1034-1043.
21. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, et al. (2009) Identification of Human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biology 7: 800-812.
22. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, et al. (2008) RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 205: 275-285.
23. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, et al. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059.
24. Kallberg E, Vogl T, Liberg D, Olsson A, Bjork P, et al. (2012) S100A9 interaction with TLR4 promotes tumor growth. PLoS One 7: e34207.
25. Hiratsuka S, Watanabe A, Aburatani H, Maru Y, (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8: 1369-1375.
26. Jennbacken K, Welen K, Olsson A, Axelsson B, Torngren M, et al. (2012) Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050). Prostate 72: 913-924.
27. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V, (2012) Coordinated regulation of myeloid cells by tumours. Nature reviews Immunology 12: 253-268.
28. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, et al. (2008) Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205: 2235-2249.
29. Jin Y, Lu Z, Ding K, Li J, Du X, et al. (2010) Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 70: 2516-2527.
30. Riva M, Kallberg E, Bjork P, Hancz D, Vogl T, et al. (2012) Induction of nuclear factor-kappaB responses by the S100A9 protein is Toll-like receptor-4-dependent. Immunology 137: 172-182.
31. Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, et al. (2006) Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 66: 1768-1778.
32. Olsson A, Bjork A, Vallon-Christersson J, Isaacs JT, Leanderson T, (2010) Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 9: 107.